osteosarcoma (Cancer)
Information
- Disease name
- osteosarcoma
- Disease ID
- DOID:3347
- Description
- "A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus)." [url:http\://en.wikipedia.org/wiki/Osteosarcoma, url:http\://www.cancer.gov/dictionary?cdrid=45395]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| RPS6KA4 | 11 | 64,359,162 | 64,372,215 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01953900 | Active, not recruiting | Phase 1 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | April 2014 | October 31, 2034 |
| NCT02076906 | Active, not recruiting | Phase 1 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | April 2014 | November 24, 2024 |
| NCT03628209 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma | October 3, 2019 | December 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT03478462 | Active, not recruiting | Phase 1 | Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | April 30, 2019 | December 2024 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT00580385 | Active, not recruiting | N/A | Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors | August 1997 | August 2024 |
| NCT03206450 | Active, not recruiting | Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors | December 6, 2017 | June 30, 2028 | |
| NCT04833582 | Active, not recruiting | Phase 1/Phase 2 | A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma | August 1, 2021 | December 30, 2023 |
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT03742193 | Active, not recruiting | Phase 2 | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy | August 11, 2019 | December 30, 2023 |
| NCT03108677 | Active, not recruiting | Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma | May 1, 2017 | December 30, 2023 | |
| NCT04803877 | Active, not recruiting | Phase 2 | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | June 4, 2021 | June 2026 |
| NCT02945800 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | October 25, 2016 | December 2024 |
| NCT02867592 | Active, not recruiting | Phase 2 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | May 18, 2017 | September 21, 2024 |
| NCT03643133 | Active, not recruiting | Phase 2 | Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients | October 23, 2018 | October 2033 |
| NCT02415816 | Active, not recruiting | N/A | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas | June 5, 2015 | April 2027 |
| NCT04571229 | Available | Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma | |||
| NCT04091295 | Available | BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | |||
| NCT00634504 | Completed | Phase 1 | Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze | May 2008 | August 2009 |
| NCT00667342 | Completed | Phase 2 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | June 3, 2008 | August 2017 |
| NCT00686738 | Completed | Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients | February 2007 | December 2015 | |
| NCT00743496 | Completed | Phase 1 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | October 8, 2008 | April 18, 2014 |
| NCT00743509 | Completed | Phase 2 | A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma | August 2008 | September 2012 |
| NCT00889057 | Completed | Phase 2 | Sorafenib in Relapsed High Grade Osteosarcoma | January 2008 | June 2011 |
| NCT00899275 | Completed | Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma | February 4, 2008 | September 30, 2023 | |
| NCT00923650 | Completed | Informed Consent in Pediatric Cancer Trials | December 9, 2008 | February 2, 2010 | |
| NCT00931931 | Completed | Phase 1 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | March 2010 | March 19, 2018 |
| NCT00978471 | Completed | Phase 2 | Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma | July 2009 | October 29, 2018 |
| NCT01005043 | Completed | Phase 1/Phase 2 | Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma | December 1, 2010 | October 2019 |
| NCT01176981 | Completed | Phase 3 | Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma | October 2010 | October 2012 |
| NCT01336803 | Completed | Phase 2 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI | August 2011 | October 2023 |
| NCT00001217 | Completed | Phase 3 | Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study | May 1987 | December 2000 |
| NCT00001436 | Completed | Phase 1 | A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma | May 1995 | September 2000 |
| NCT00026780 | Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | September 24, 2001 | October 7, 2020 | |
| NCT00038207 | Completed | Phase 2 | Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | June 2000 | September 2005 |
| NCT00093080 | Completed | Phase 2 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | October 2004 | November 2008 |
| NCT00132158 | Completed | Phase 1 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | September 2005 | October 2011 |
| NCT00145639 | Completed | Phase 2 | Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma | May 1999 | May 2006 |
| NCT00180908 | Completed | Phase 3 | Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children | June 1994 | |
| NCT00187109 | Completed | Phase 1/Phase 2 | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | June 2000 | February 2007 |
| NCT00407433 | Completed | Phase 2 | Clinical Studies of Gemcitabine-Oxaliplatin | ||
| NCT00503295 | Completed | Phase 2 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung | June 2007 | April 2011 |
| NCT00504140 | Completed | Phase 2 | Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma | November 1996 | March 2009 |
| NCT00520936 | Completed | Phase 2 | A Study of Pemetrexed in Children With Recurrent Cancer | September 2007 | February 2010 |
| NCT00523419 | Completed | Phase 2 | Chemotherapy for Patients With Osteosarcoma | September 2007 | June 2010 |
| NCT00572130 | Completed | Phase 2 | Phase II Study of Intravenous Rexin-G in Osteosarcoma | December 2007 | June 2011 |
| NCT00586846 | Completed | Phase 2 | Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma | July 2003 | February 2009 |
| NCT00588510 | Completed | Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction | January 2000 | September 2011 | |
| NCT00631631 | Completed | Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | January 2008 | October 2012 | |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT00001209 | Completed | Phase 1 | A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors | October 1986 | August 2000 |
| NCT01459484 | Completed | Phase 2 | ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma | June 23, 2011 | April 30, 2024 |
| NCT01518413 | Completed | Phase 1 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | December 2011 | January 2015 |
| NCT01615640 | Completed | Diffusion Study on Patients With Osteosarcoma | September 2010 | June 7, 2019 | |
| NCT01661400 | Completed | Phase 1 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | October 26, 2012 | December 27, 2023 |
| NCT01674101 | Completed | N/A | Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | September 2012 | November 2015 |
| NCT01807143 | Completed | Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma | January 2010 | ||
| NCT01848457 | Completed | Phase 2 | Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy | April 2013 | October 1, 2016 |
| NCT01987102 | Completed | Phase 1/Phase 2 | Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. | December 2013 | January 3, 2017 |
| NCT02094625 | Completed | Phase 1 | NAC to Prevent Cisplatin-induced Hearing Loss | March 2016 | August 2021 |
| NCT02100891 | Completed | Phase 2 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | March 20, 2013 | July 15, 2020 |
| NCT02107963 | Completed | Phase 1 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | February 28, 2014 | January 31, 2017 |
| NCT02132182 | Completed | Monocyte Phenotypic and Functional Differences | October 2014 | March 23, 2017 | |
| NCT02159443 | Completed | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | July 15, 2014 | April 24, 2020 | |
| NCT02162732 | Completed | N/A | Molecular-Guided Therapy for Childhood Cancer | July 8, 2014 | January 18, 2024 |
| NCT02223052 | Completed | Phase 1 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | October 27, 2014 | December 18, 2018 |
| NCT02383901 | Completed | A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX | September 2014 | May 2016 | |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT02429973 | Completed | Phase 2 | Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma | July 2012 | April 2015 |
| NCT02432274 | Completed | Phase 1/Phase 2 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | December 29, 2014 | July 20, 2022 |
| NCT02517918 | Completed | Phase 1 | Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma | February 2015 | November 16, 2021 |
| NCT02711007 | Completed | Phase 2/Phase 3 | Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | March 2016 | January 8, 2018 |
| NCT02982941 | Completed | Phase 1 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | December 2016 | May 22, 2019 |
| NCT02986503 | Completed | European Study in Bone Sarcoma Patients Over 40 Years | January 2002 | November 2016 | |
| NCT03006848 | Completed | Phase 2 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | February 16, 2017 | March 18, 2020 |
| NCT03718091 | Completed | Phase 2 | M6620 (VX-970) in Selected Solid Tumors | January 8, 2019 | July 8, 2020 |
| NCT03911245 | Completed | Osteosarcoma in Patients Older Than 40 Years. Prognostic Factors and Survival | January 1, 2018 | December 31, 2018 | |
| NCT03997747 | Completed | Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS | August 13, 2019 | December 1, 2021 | |
| NCT04154189 | Completed | Phase 2 | A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | March 23, 2020 | August 17, 2023 |
| NCT04248959 | Completed | N/A | Prehabilitation to Improve Cancer Surgery Outcomes in AYA Patients With Extremity Sarcomas | February 2, 2022 | April 26, 2023 |
| NCT04383288 | Completed | ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities | July 2, 2014 | October 17, 2020 | |
| NCT04956198 | Completed | Drug Sensitivity and Mutation Profiling | November 17, 2020 | December 31, 2022 | |
| NCT05024253 | Completed | Phase 3 | Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. | August 2, 2021 | February 1, 2024 |
| NCT05093101 | Completed | The Prognostic Value of Serum Biomarkers in Osteosarcoma | July 12, 2021 | December 22, 2021 | |
| NCT05093322 | Completed | Phase 1/Phase 2 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | November 30, 2021 | April 25, 2023 |
| NCT05101655 | Completed | Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma | October 1, 2020 | September 30, 2022 | |
| NCT05801887 | Completed | N/A | Extracorporeal Shock Wave Therapy on Osteoblast-Like Cells In- Vitro Study | October 22, 2021 | November 6, 2022 |
| NCT06162962 | Completed | Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient | January 1, 2000 | November 23, 2023 | |
| NCT05772312 | Enrolling by invitation | Quality of Life of Patients With Bone Tumor of the Lower Limbs Treated With Salvage Surgery | January 17, 2023 | December 31, 2024 | |
| NCT06125171 | Not yet recruiting | Phase 2 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | January 2024 | December 2025 |
| NCT03358628 | Not yet recruiting | Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma | February 1, 2018 | January 31, 2025 | |
| NCT04319874 | Not yet recruiting | Phase 2 | Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma | September 15, 2020 | September 15, 2025 |
| NCT06341712 | Not yet recruiting | Phase 2 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma | June 13, 2024 | June 15, 2028 |
| NCT06217003 | Not yet recruiting | Phase 2 | Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma | February 1, 2024 | August 1, 2025 |
| NCT05515068 | Not yet recruiting | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas | September 2022 | March 2032 | |
| NCT05535283 | Not yet recruiting | Assessing Clinical Trial Experiences of Patients With Osteosarcoma | October 2024 | October 2026 | |
| NCT06235125 | Not yet recruiting | Phase 1 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | January 20, 2024 | January 20, 2026 |
| NCT05590572 | Not yet recruiting | Phase 1/Phase 2 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | January 2023 | December 2027 |
| NCT05062707 | Recruiting | Early Ageing During Therapy in AYA Cancer Patients | February 10, 2022 | July 2025 | |
| NCT04995003 | Recruiting | Phase 1 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | December 7, 2021 | December 31, 2040 |
| NCT05057130 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | January 10, 2022 | December 2024 |
| NCT05642455 | Recruiting | Phase 1/Phase 2 | SPEARHEAD-3 Pediatric Study | September 1, 2023 | July 30, 2038 |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT00840047 | Recruiting | Phase 2 | Methionine PET/CT Studies In Patients With Cancer | July 20, 2009 | July 27, 2027 |
| NCT03225872 | Recruiting | Biology of Osteosarcoma (BOOST) Registry and Biobank | January 3, 2017 | December 2050 | |
| NCT03242382 | Recruiting | Phase 2 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. | March 31, 2017 | September 30, 2024 |
| NCT05588648 | Recruiting | Phase 1/Phase 2 | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | March 31, 2023 | November 2025 |
| NCT03373097 | Recruiting | Phase 1/Phase 2 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | January 5, 2018 | December 2027 |
| NCT05926492 | Recruiting | Phase 2 | A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma | January 9, 2024 | July 2026 |
| NCT03442465 | Recruiting | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | February 14, 2018 | February 14, 2025 | |
| NCT03458520 | Recruiting | Pediatric PET/MR Image Registry | February 1, 2018 | March 1, 2025 | |
| NCT05970497 | Recruiting | Phase 1 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | October 31, 2023 | July 2026 |
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT03496402 | Recruiting | N/A | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | April 20, 2018 | August 19, 2027 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT05395741 | Recruiting | Phase 1/Phase 2 | Regorafenib in Patients With Refractory Primary Bone Tumors | April 28, 2022 | December 31, 2025 |
| NCT05328258 | Recruiting | Phase 3 | Use of GnRHa During Chemotherapy for Fertility Protection | March 31, 2023 | January 31, 2032 |
| NCT05312411 | Recruiting | Phase 1 | A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma | May 20, 2022 | April 30, 2040 |
| NCT06114225 | Recruiting | Phase 2 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial | June 1, 2023 | December 30, 2026 |
| NCT03721068 | Recruiting | Phase 1 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | February 19, 2019 | June 19, 2039 |
| NCT05851456 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors | April 10, 2023 | April 2026 |
| NCT05830123 | Recruiting | Phase 2 | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | June 8, 2023 | December 31, 2027 |
| NCT03900793 | Recruiting | Phase 1 | Losartan + Sunitinib in Treatment of Osteosarcoma | August 26, 2019 | February 2027 |
| NCT06117878 | Recruiting | Early Phase 1 | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma | September 1, 2022 | September 1, 2024 |
| NCT01790152 | Recruiting | Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | March 5, 2014 | December 31, 2025 | |
| NCT03960177 | Recruiting | Early Phase 1 | Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma | March 27, 2019 | June 1, 2026 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04040205 | Recruiting | Phase 2 | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | October 7, 2019 | June 1, 2027 |
| NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
| NCT06387485 | Recruiting | N/A | A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning | March 1, 2024 | April 1, 2025 |
| NCT04132895 | Recruiting | ICONIC: Improving Outcomes Through Collaboration in OsteosarComa | October 25, 2019 | January 31, 2027 | |
| NCT06156410 | Recruiting | Phase 1 | Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma | October 24, 2023 | November 2028 |
| NCT06438783 | Recruiting | Phase 1 | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors | February 15, 2024 | February 2026 |
| NCT04282044 | Recruiting | Phase 1 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | January 8, 2021 | October 2026 |
| NCT00411060 | Recruiting | Clinical Orthopaedic Data Bank (Acute and Chronic) | January 2007 | July 14, 2025 | |
| NCT05235165 | Recruiting | Phase 3 | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | April 1, 2022 | March 31, 2031 |
| NCT05194605 | Recruiting | Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma | January 1, 2021 | December 31, 2024 | |
| NCT05779670 | Recruiting | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | January 1, 2023 | December 31, 2025 | |
| NCT06171282 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | July 12, 2023 | July 12, 2026 |
| NCT04417062 | Recruiting | Phase 2 | Olaparib With Ceralasertib in Recurrent Osteosarcoma | November 24, 2020 | June 1, 2025 |
| NCT05182164 | Recruiting | Phase 2 | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | April 25, 2022 | October 31, 2025 |
| NCT06017518 | Recruiting | An Observational Study of Local Relapse After High Grade Osteosarcoma | June 13, 2022 | June 30, 2026 | |
| NCT06029218 | Recruiting | N/A | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy | September 13, 2023 | October 1, 2031 |
| NCT04671693 | Recruiting | N/A | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | December 24, 2020 | April 24, 2028 |
| NCT04698785 | Recruiting | Phase 2 | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | July 21, 2021 | July 21, 2026 |
| NCT04735289 | Recruiting | Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma | March 10, 2021 | December 31, 2024 | |
| NCT06384404 | Recruiting | Upfront Surgical Resection for Osteosarcoma | March 25, 2024 | December 31, 2029 | |
| NCT04758000 | Recruiting | Phase 2 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse | March 1, 2021 | July 2027 |
| NCT06064682 | Recruiting | An Organoid-based Functional Precision Medicine Trial in Osteosarcoma | February 12, 2024 | January 1, 2027 | |
| NCT05942456 | Recruiting | Soluble B7-H3 as a Biomarker for Osteosarcoma | June 5, 2023 | December 31, 2024 | |
| NCT06324916 | Recruiting | Donor Site Morbidity After Free Vascularized Fibular Graft | January 10, 2024 | December 30, 2026 | |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT04616560 | Suspended | Phase 2 | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma | March 8, 2021 | March 31, 2025 |
| NCT02441309 | Terminated | Phase 2 | A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) | October 2014 | November 4, 2016 |
| NCT02536183 | Terminated | Phase 1 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | October 2016 | October 2022 |
| NCT02581384 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | January 2017 | August 2020 |
| NCT02718482 | Terminated | Phase 2 | Phase II Trial for the Treatment of Relapsed Osteosarcoma | April 6, 2016 | January 7, 2019 |
| NCT03013127 | Terminated | Phase 2 | A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery | May 30, 2017 | January 31, 2019 |
| NCT03422679 | Terminated | Phase 1/Phase 2 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | December 5, 2017 | November 11, 2022 |
| NCT03458728 | Terminated | Phase 1/Phase 2 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | April 30, 2018 | February 1, 2023 |
| NCT00752206 | Terminated | Phase 2 | A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | March 2009 | December 2017 |
| NCT00673179 | Terminated | N/A | Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy | May 2008 | November 2010 |
| NCT03860207 | Terminated | Phase 1/Phase 2 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | February 22, 2019 | October 20, 2021 |
| NCT00634322 | Terminated | Phase 2 | High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma | October 2008 | April 2009 |
| NCT04365660 | Terminated | Phase 2 | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | January 28, 2021 | July 22, 2021 |
| NCT00617890 | Terminated | Phase 2 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | February 1, 2008 | August 31, 2013 |
| NCT00615628 | Terminated | Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: | April 2002 | December 2009 | |
| NCT00615329 | Terminated | Huntsman Biopsy Study | April 2003 | February 2014 | |
| NCT00428272 | Terminated | Phase 1 | HGS-ETR2 to Treat Children With Solid Tumors | December 4, 2006 | October 9, 2015 |
| NCT04861948 | Terminated | Phase 1 | IBI188 Combination Therapy in Solid Tumors | May 25, 2021 | July 30, 2022 |
| NCT01258634 | Terminated | Phase 1 | A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response | July 2010 | November 2011 |
| NCT01491594 | Terminated | Phase 1 | Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | April 2012 | March 2013 |
| NCT01759303 | Terminated | Phase 2 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | April 2013 | May 2017 |
| NCT01882231 | Terminated | N/A | Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma | March 2013 | April 25, 2016 |
| NCT01986829 | Terminated | Phase 2 | Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy | February 3, 2014 | August 8, 2017 |
| NCT01987596 | Terminated | Phase 3 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | August 2013 | June 2018 |
| NCT02022358 | Terminated | Phase 2 | Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? | July 2007 | June 2015 |
| NCT01194284 | Terminated | Surveillance Study of Patients With Newly Diagnosed Osteosarcoma | December 2011 | December 2013 | |
| NCT04461223 | Unknown status | Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR | December 1, 2019 | December 1, 2021 | |
| NCT04351308 | Unknown status | Phase 2 | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma | May 1, 2020 | December 31, 2022 |
| NCT04316091 | Unknown status | Phase 1 | A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma | September 1, 2020 | August 31, 2023 |
| NCT01669369 | Unknown status | Phase 4 | Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma | January 2013 | December 2023 |
| NCT04294511 | Unknown status | Phase 2 | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma | December 26, 2019 | September 16, 2023 |
| NCT01758666 | Unknown status | N/A | A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy | September 2012 | December 2016 |
| NCT03390946 | Unknown status | Phase 2 | Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma | February 1, 2018 | December 31, 2020 |
| NCT03362086 | Unknown status | The Osteosarcoma Biobank in Peking University People's Hospital | February 1, 2018 | February 1, 2024 | |
| NCT01002092 | Unknown status | Phase 2 | A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma | February 2009 | December 2014 |
| NCT04945512 | Unknown status | N/A | Efficacy of Epidural Analgesia in Lower Extremity Osteosarcoma | November 7, 2021 | September 20, 2022 |
| NCT04886765 | Unknown status | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | May 2021 | May 2024 |
| NCT03063983 | Unknown status | Phase 2 | Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma | January 2, 2017 | January 31, 2022 |
| NCT04864821 | Unknown status | Early Phase 1 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | May 14, 2021 | May 14, 2023 |
| NCT04757064 | Unknown status | N/A | Efficacy of Exercise Program on Osteosarcoma Patients | August 7, 2021 | April 2022 |
| NCT02982486 | Unknown status | Phase 2 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | December 2017 | December 2020 |
| NCT01780779 | Unknown status | Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults | June 2009 | June 2014 | |
| NCT03932058 | Unknown status | Proteomics Research of Osteosarcoma | September 1, 2018 | September 1, 2020 | |
| NCT03676985 | Unknown status | Phase 1/Phase 2 | A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma | October 10, 2018 | June 23, 2023 |
| NCT01807468 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | May 2013 | June 2019 |
| NCT00689195 | Unknown status | Phase 1/Phase 2 | Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma | May 2008 | June 2013 |
| NCT01242072 | Unknown status | Phase 1 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | November 2010 | December 2012 |
| NCT00691236 | Unknown status | Phase 2/Phase 3 | Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma | May 2008 | August 2013 |
| NCT02856048 | Unknown status | Phase 2/Phase 3 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer | November 23, 2016 | February 2021 |
| NCT02013336 | Unknown status | Phase 1 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | December 2013 | December 2023 |
| NCT01112800 | Withdrawn | Markers of Anthracycline-Related Cardiac Muscle Injury | May 2010 | January 2013 | |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT01492569 | Withdrawn | N/A | Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting | May 2012 | |
| NCT03209869 | Withdrawn | Phase 1 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 | March 12, 2018 | September 7, 2022 |
| NCT02689336 | Withdrawn | Phase 2 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | August 6, 2016 | May 31, 2020 |
| NCT01236586 | Withdrawn | Phase 1 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | October 8, 2010 | April 13, 2011 |
| NCT01130623 | Withdrawn | Phase 1 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | May 10, 2010 | November 18, 2011 |
| NCT03612466 | Withdrawn | Phase 1 | A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy | August 2022 | September 2024 |
| NCT02557854 | Withdrawn | Phase 1 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | December 2016 | March 16, 2019 |
- Disase is a (Disease Ontology)
- DOID:0080639
- Cross Reference ID (Disease Ontology)
- GARD:7284
- Cross Reference ID (Disease Ontology)
- ICDO:9180/3
- Cross Reference ID (Disease Ontology)
- MESH:D012516
- Cross Reference ID (Disease Ontology)
- MESH:D018213
- Cross Reference ID (Disease Ontology)
- MIM:259500
- Cross Reference ID (Disease Ontology)
- NCI:C9145
- Cross Reference ID (Disease Ontology)
- ORDO:668
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:189878003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0029463
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206639
- Exact Synonym (Disease Ontology)
- bone tissue neoplasm
- Exact Synonym (Disease Ontology)
- Osteogenic sarcoma
- Exact Synonym (Disease Ontology)
- osteoid sarcoma
- Exact Synonym (Disease Ontology)
- Skeletal sarcoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002669
- OrphaNumber from OrphaNet (Orphanet)
- 668
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012516